Zephyr Illuminate pools disparate data for predictive analytics for commercial operations
Coming out of the “big data” and cloud-computing worlds, there is an evolving and as-yet unnamed new type of IT service; Zephyr Health calls its version “insights as a service;” others use the term predictive analytics. In any case, the San Francisco company, with products already in use at most major pharma companies, is launching Illuminate, which it says represents its next generation of analytics capabilities for clinical and commercial operations in life sciences.
According to the company, Illuminate gather disparate public and private data—health system affiliations, prescriber activity, manufacturer sales and promotion data and others—and unites them into a unified picture of the marketplace for drugs, devices and related therapies. The system is especially attuned to new product launch activity: “Illuminate maximizes time to market for life sciences companies and provides market metrics to instrument their business with facts at every stage of product development, launch and commercialization," said William King, president, in a statement.
Another feature of Illuminate is a Recommendation Engine, which clients can use to make predictive analysis of their data. In this regard, the Zephyr product is similar to efforts by others, such as Veeva’s Suggestions solution or Shyft Analytics' (Waltham, MA) Real World Evidence offering, to guide clients through the growing thicket of data sources now available. Some of these tools are valuable complements to the CRM systems that sales reps can use in the field; other implementations guide the home office in areas like territory management, KOL relationships and market access issues with payers.
Stay ahead in the life sciences industry with Pharmaceutical Commerce, the latest news, trends, and strategies in drug distribution, commercialization, and market access.
Study Connects COVID-19 Treatment Disparities to Gaps in Testing and Virtual Access
July 11th 2025New research finds that nearly half of the racial and ethnic disparities in outpatient COVID-19 antiviral prescriptions stem from encounter-level care barriers, such as limited access to rapid tests and telehealth, which emphasizes the need for systemic and practice-level reforms.